Patient-reported outcomes of rimegepant for acute and preventive treatment of migraine in China: a prospective, multicenter, real-world study
Abstract
BACKGROUND: Migraine imposes a substantial global burden, with unmet patient-centered therapeutic needs. Rimegepant, a CGRP receptor antagonist, has trial-proven efficacy, but real-world evidence for its dual acute and preventive use in Chinese migraine populations is limited. This study evaluated its effectiveness in Chinese patients using patient-reported outcomes. METHODS: A multicenter, single-arm, prospective, non-interventional observational study was conducted across five hospitals in the Guangdong-Hong Kong-Macao Greater Bay Area, China. A total of 120 adult migraine patients who were prescribed rimegepant for either acute (AT) or preventive treatment (PT) were enrolled. Patient-reported outcomes were assessed at baseline and after 4 weeks using Headache Impact Test (HIT-6), Treatment Satisfaction Questionnaire for Medication (TSQM), the European Five-Dimension Five-Level Health Scale (EQ-5D-5L) and the Work Productivity and Activity Impairment Questionnaire - General Health (WPAI-GH). We employed the Wilcoxon signed-rank test for within-group comparisons of pre- and post-treatment scale scores, with statistically significant defined as a two-tailed p-value < 0.05. RESULTS: A total of 120 migraine patients meeting all inclusion criteria were enrolled but 12 potential participants (10.0%) did not initiate rimegepant therapy. The study was completed by 108 patients (median age 37.0 (31.5,46.0) years; 83% female), including 89 in the AT group and 19 in the PT group.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 120 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.